Royalty Pharma plc (RPRX) reported Q2 cash receipts of $536 million versus the consensus estimate of $532.56 million.
GUIDANCE:
Royalty Pharma plc sees FY2022 adjusted cash receipts $2.275-2.35 billion, versus the consensus of $2.28 billion.
Royalty Pharma plc (RPRX) reported Q2 cash receipts of $536 million versus the consensus estimate of $532.56 million.
GUIDANCE:
Royalty Pharma plc sees FY2022 adjusted cash receipts $2.275-2.35 billion, versus the consensus of $2.28 billion.